Arcus Biosciences, Inc. (RCUS)
29.21
-1.38
(-4.51%)
USD |
NYSE |
Aug 28, 16:00
29.18
-0.03
(-0.10%)
After-Hours: 20:00
Arcus Biosciences Gross Profit Margin (Quarterly) : 95.12% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 95.12% |
| March 31, 2026 | 88.24% |
| December 31, 2025 | 90.91% |
| September 30, 2025 | 92.31% |
| June 30, 2025 | 98.75% |
| March 31, 2025 | 89.29% |
| December 31, 2024 | 88.46% |
| September 30, 2024 | 95.83% |
| June 30, 2024 | 94.87% |
| March 31, 2024 | 97.93% |
| December 31, 2023 | 83.87% |
| September 30, 2023 | 90.62% |
| June 30, 2023 | 86.21% |
| March 31, 2023 | 84.00% |
| December 31, 2022 | 89.81% |
| September 30, 2022 | 89.25% |
| June 30, 2022 | 86.81% |
| March 31, 2022 | 80.93% |
| Date | Value |
|---|---|
| December 31, 2021 | 99.30% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 38.72% |
| September 30, 2017 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 77.40% |
| AVITA Medical, Inc. | 81.87% |
| Iovance Biotherapeutics, Inc. | 46.54% |
| Editas Medicine, Inc. | 96.50% |
| Recursion Pharmaceuticals, Inc. | -202.4% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -88.33% |
| Return on Assets | -41.56% |
| Return on Invested Capital | -70.79% |
| Profit Margin (Quarterly) | -222.0% |
| Operating Margin (Quarterly) | -234.1% |
| Return on Net Operating Assets | -688.6% |